Meeting
2016 Genitourinary Cancers Symposium
Experience with IL-2 in metastatic renal cell carcinoma after treatment with one or more targeted therapies.
Authors
Hanh P. Mai
Loyola University Medical Center, Chicago, IL
Hanh P. Mai , Peter Vu , Arjune Patel , Joseph Clark , Elizabeth Henry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 622)
DOI
10.1200/jco.2016.34.2_suppl.622
Abstract #
622
Poster Bd #
J19
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
High-dose interleukin-2 (HD IL-2) for metastatic renal CELL carcinoma (mRCC): Contemporary utilization trends in the United States.
First Author: Christopher B. Allard
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Poster
2022 ASCO Annual Meeting
A first-in-human, multicenter, phase 1/2, open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solid tumors.
First Author: Meredith McKean
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst